KR102663113B1 - Cdk9 저해제로서의 폴리사이클릭 아미드 유도체 - Google Patents

Cdk9 저해제로서의 폴리사이클릭 아미드 유도체 Download PDF

Info

Publication number
KR102663113B1
KR102663113B1 KR1020187002262A KR20187002262A KR102663113B1 KR 102663113 B1 KR102663113 B1 KR 102663113B1 KR 1020187002262 A KR1020187002262 A KR 1020187002262A KR 20187002262 A KR20187002262 A KR 20187002262A KR 102663113 B1 KR102663113 B1 KR 102663113B1
Authority
KR
South Korea
Prior art keywords
pyridin
chloro
cyclohexanecarboxamide
acetamido
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187002262A
Other languages
English (en)
Korean (ko)
Other versions
KR20180021830A (ko
Inventor
커트 고든 파이크
버나드 크리스토프 바를라암
자넷 호킨스
크리스토퍼 데 사비
멜리사 마리 바스바인더
알렉산더 허드
미쉘 램
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20180021830A publication Critical patent/KR20180021830A/ko
Application granted granted Critical
Publication of KR102663113B1 publication Critical patent/KR102663113B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Detergent Compositions (AREA)
KR1020187002262A 2015-06-29 2016-06-27 Cdk9 저해제로서의 폴리사이클릭 아미드 유도체 Active KR102663113B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562185852P 2015-06-29 2015-06-29
US62/185,852 2015-06-29
PCT/EP2016/064899 WO2017001354A1 (en) 2015-06-29 2016-06-27 Polycyclic amide derivatives as cdk9 inhibitors

Publications (2)

Publication Number Publication Date
KR20180021830A KR20180021830A (ko) 2018-03-05
KR102663113B1 true KR102663113B1 (ko) 2024-05-02

Family

ID=56292699

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187002262A Active KR102663113B1 (ko) 2015-06-29 2016-06-27 Cdk9 저해제로서의 폴리사이클릭 아미드 유도체

Country Status (38)

Country Link
US (4) US9845331B2 (enExample)
EP (2) EP3313838B1 (enExample)
JP (1) JP6997627B2 (enExample)
KR (1) KR102663113B1 (enExample)
CN (1) CN107873028B (enExample)
AR (1) AR105179A1 (enExample)
AU (1) AU2016286200B2 (enExample)
BR (1) BR122019013677B1 (enExample)
CA (1) CA2989499C (enExample)
CL (1) CL2017003306A1 (enExample)
CO (1) CO2017013713A2 (enExample)
CR (2) CR20170596A (enExample)
CY (2) CY1122111T1 (enExample)
DK (2) DK3539961T3 (enExample)
DO (2) DOP2017000295A (enExample)
EA (1) EA035383B1 (enExample)
ES (2) ES2902148T3 (enExample)
HR (2) HRP20190748T1 (enExample)
HU (2) HUE057343T2 (enExample)
IL (1) IL256393B (enExample)
LT (2) LT3539961T (enExample)
ME (1) ME03404B (enExample)
MX (1) MX371034B (enExample)
MY (1) MY201673A (enExample)
NI (1) NI201700174A (enExample)
PE (1) PE20180530A1 (enExample)
PH (1) PH12017502334B1 (enExample)
PL (2) PL3313838T3 (enExample)
PT (2) PT3313838T (enExample)
RS (2) RS62781B1 (enExample)
SI (2) SI3539961T1 (enExample)
SM (2) SMT201900298T1 (enExample)
SV (1) SV2017005598A (enExample)
TN (1) TN2017000486A1 (enExample)
TR (1) TR201909286T4 (enExample)
TW (1) TWI723028B (enExample)
WO (1) WO2017001354A1 (enExample)
ZA (1) ZA201800563B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019058348A1 (en) 2017-09-25 2019-03-28 Astrazeneca Ab COMBINATION OF A BTK INHIBITOR AND A CDK9 INHIBITOR TO TREAT CANCER
WO2019074748A1 (en) * 2017-10-09 2019-04-18 Merck Sharp & Dohme Corp. NOVEL SUBSTITUTED PHENYL-OXETANE AND PHENYLTETRAHYDROFURAN COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO)
CN108129288B (zh) * 2017-12-27 2021-01-22 上海毕得医药科技股份有限公司 一种反式-3-羟基环丁基甲酸的合成方法
TWI810397B (zh) 2018-11-14 2023-08-01 瑞典商阿斯特捷利康公司 治療癌症之方法
CN114008046B (zh) * 2019-06-27 2023-08-18 南京明德新药研发有限公司 作为cdk9抑制剂的氮杂吲哚连吡唑类化合物
WO2021050824A1 (en) 2019-09-11 2021-03-18 Prelude Therapeutics Incorporated Cdk inhibitors and their use as pharmaceuticals
EP4074699A4 (en) * 2019-12-09 2024-01-03 CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. COMPOUND USEFUL AS CYCLIN-DEPENDENT KINASE 9 INHIBITOR AND USE THEREOF
EP4140997A4 (en) * 2020-05-12 2023-09-06 Suzhou Alphama Biotechnology Co., Ltd. PYRIDINE ACETAMIDE DERIVATIVE AS CDK INHIBITOR, PREPARATION METHOD AND USE THEREOF
EP4141004A4 (en) * 2020-05-12 2023-08-23 Suzhou Alphama Biotechnology Co., Ltd. POLYCYCLIC AMIDE DERIVATIVE SERVING AS A CDK9 INHIBITOR, METHOD FOR PREPARING IT AND ITS USE
EP4171654A1 (en) 2020-06-24 2023-05-03 AstraZeneca UK Limited Combination of antibody-drug conjugate and cdk9 inhibitor
US20230271942A1 (en) 2020-08-07 2023-08-31 Pharmablock Sciences (Nanjing), Inc. Cdk9 inhibitor and use thereof
TWI809330B (zh) * 2020-11-20 2023-07-21 大陸商勁方醫藥科技(上海)有限公司 Cdk9抑制劑的多晶型物及其製法和用途
WO2022247785A1 (zh) * 2021-05-24 2022-12-01 石药集团中奇制药技术（石家庄）有限公司 一种周期蛋白依赖性激酶9抑制剂的用途
CN115381824B (zh) * 2021-05-24 2024-11-05 石药集团中奇制药技术（石家庄）有限公司 周期蛋白依赖性激酶9抑制剂的用途
CN117813289A (zh) * 2021-07-14 2024-04-02 上海海雁医药科技有限公司 吡唑衍生物及其中间体和制备方法
CN115703738B (zh) * 2021-08-16 2024-06-21 中国科学院上海药物研究所 含2-芳杂环取代的脲类化合物、其制备方法和用途
JP2025501773A (ja) * 2021-12-23 2025-01-23 ザ・カトリック・ユニヴェルシテイト・ルーバン Ｙａｐ／ｔａｚ－ｔｅａｄを阻害するためのテトラヒドロピラゾロピリミジン及び関連類似体
JP2025528223A (ja) 2022-08-17 2025-08-26 コリア リサーチ インスティテュート オブ ケミカル テクノロジー Ｃｄｋ２及び／又はｃｄｋ９の抑制又は分解用化合物及びこれらの医薬用途
CN117659022A (zh) * 2022-09-06 2024-03-08 苏州阿尔脉生物科技有限公司 脲基取代吡啶类化合物、包含其的药物组合物及其医药用途
US20240360075A1 (en) * 2023-04-19 2024-10-31 Alcon Inc. N-substituted c6 cyclyl carboxamide compounds and uses thereof
WO2025076115A1 (en) * 2023-10-02 2025-04-10 Prelude Therapeutics Incorporated Cdk inhibitors and their use as pharmaceuticals

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008132138A1 (en) 2007-04-25 2008-11-06 Ingenium Pharmaceuticals Gmbh Derivatives of 4,6-disubstituted aminopyrimidines
US20120157433A1 (en) 2009-09-04 2012-06-21 Pfister Keith B Heteroaryl Compounds as Kinase Inhibitors
WO2012101064A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
WO2012101063A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyridine biaryl compounds and their uses
US20140275027A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors
WO2014160017A1 (en) 2013-03-13 2014-10-02 Abbvie Inc. Pyridine cdk9 kinase inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008133192A1 (ja) 2007-04-19 2008-11-06 Takeda Pharmaceutical Company Limited 縮合イミダゾール化合物およびその用途
JP5379787B2 (ja) 2007-04-24 2013-12-25 インゲニウム ファーマシューティカルズ ジーエムビーエイチ プロテインキナーゼの阻害剤
WO2008129069A1 (en) 2007-04-24 2008-10-30 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
EP2137166B1 (en) 2007-04-24 2012-05-30 Ingenium Pharmaceuticals GmbH 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases
ES2539518T3 (es) 2007-04-24 2015-07-01 Astrazeneca Ab Inhibidores de proteínas quinasas
CN101889004B (zh) 2007-10-12 2014-09-10 阿斯利康公司 蛋白激酶抑制剂
US20110113038A1 (en) 2009-11-12 2011-05-12 International Business Machines Corporation Search term security
GB201002911D0 (en) 2010-02-19 2010-04-07 Medical Res Council Compound
KR20130016244A (ko) 2010-03-10 2013-02-14 인게니움 파르마코이티칼스 게엠베하 단백질 키나아제의 억제제
AR081810A1 (es) * 2010-04-07 2012-10-24 Bayer Cropscience Ag Piridinilpirazoles biciclicos
WO2012066065A1 (en) 2010-11-17 2012-05-24 Novartis Ag Phenyl-heteroaryl amine compounds and their uses
WO2012101062A1 (en) * 2011-01-28 2012-08-02 Novartis Ag Substituted bi-heteroaryl compounds as cdk9 inhibitors and their uses
UA114410C2 (uk) 2011-10-06 2017-06-12 Байєр Інтеллектуал Проперті Гмбх Гетероциклілпіри(mi)динілпіразол
CA2901929A1 (en) 2013-03-13 2014-10-02 Abbvie Inc. Cdk9 kinase inhibitors
AU2014244194A1 (en) 2013-03-14 2015-09-10 Abbvie Inc. Pyrrolopyrimindine CDK9 kinase inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008132138A1 (en) 2007-04-25 2008-11-06 Ingenium Pharmaceuticals Gmbh Derivatives of 4,6-disubstituted aminopyrimidines
US20120157433A1 (en) 2009-09-04 2012-06-21 Pfister Keith B Heteroaryl Compounds as Kinase Inhibitors
WO2012101064A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
WO2012101063A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyridine biaryl compounds and their uses
WO2014160017A1 (en) 2013-03-13 2014-10-02 Abbvie Inc. Pyridine cdk9 kinase inhibitors
US20140275027A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors

Also Published As

Publication number Publication date
ES2902148T3 (es) 2022-03-25
EP3539961B1 (en) 2021-10-06
PL3539961T3 (pl) 2022-02-14
TW201718573A (zh) 2017-06-01
AR105179A1 (es) 2017-09-13
LT3539961T (lt) 2021-12-27
DK3313838T3 (da) 2019-06-11
US20220340592A1 (en) 2022-10-27
PT3313838T (pt) 2019-06-24
US20160376287A1 (en) 2016-12-29
AU2016286200A1 (en) 2018-02-08
RS62781B1 (sr) 2022-01-31
CR20170596A (es) 2018-07-04
PL3313838T3 (pl) 2019-08-30
NI201700174A (es) 2018-10-19
ES2728356T3 (es) 2019-10-23
BR112017027394A2 (pt) 2018-11-06
CO2017013713A2 (es) 2018-03-28
DOP2017000295A (es) 2017-12-31
WO2017001354A1 (en) 2017-01-05
CA2989499C (en) 2023-10-31
CA2989499A1 (en) 2017-01-05
PT3539961T (pt) 2021-12-20
ZA201800563B (en) 2022-08-31
RS58712B1 (sr) 2019-06-28
CN107873028B (zh) 2021-02-02
CR20210297A (es) 2021-09-29
JP6997627B2 (ja) 2022-01-17
SI3539961T1 (sl) 2022-02-28
HRP20211970T1 (hr) 2022-03-18
DK3539961T3 (da) 2022-01-03
SI3313838T1 (sl) 2019-06-28
SV2017005598A (es) 2018-02-23
CL2017003306A1 (es) 2018-06-29
AU2016286200B2 (en) 2018-10-04
US11352369B2 (en) 2022-06-07
TR201909286T4 (tr) 2019-07-22
MY201673A (en) 2024-03-12
LT3313838T (lt) 2019-06-10
CN107873028A (zh) 2018-04-03
TN2017000486A1 (en) 2019-04-12
KR20180021830A (ko) 2018-03-05
MX371034B (es) 2020-01-13
DOP2018000207A (es) 2018-10-15
US20210171541A1 (en) 2021-06-10
BR122019013677B1 (pt) 2024-01-02
US10717746B2 (en) 2020-07-21
SMT202200005T1 (it) 2022-03-21
IL256393A (en) 2018-02-28
CY1125066T1 (el) 2023-03-24
SMT201900298T1 (it) 2019-07-11
EP3539961A1 (en) 2019-09-18
HUE043440T2 (hu) 2019-08-28
ME03404B (me) 2020-01-20
MX2017016244A (es) 2018-04-20
HRP20190748T1 (hr) 2019-06-14
US20180093998A1 (en) 2018-04-05
PE20180530A1 (es) 2018-03-19
EP3313838B1 (en) 2019-04-03
US9845331B2 (en) 2017-12-19
EA035383B1 (ru) 2020-06-04
EP3313838A1 (en) 2018-05-02
IL256393B (en) 2021-12-01
HUE057343T2 (hu) 2022-05-28
CY1122111T1 (el) 2020-11-25
EA201890094A1 (ru) 2018-07-31
JP2018522869A (ja) 2018-08-16
PH12017502334A1 (en) 2018-06-25
TWI723028B (zh) 2021-04-01
PH12017502334B1 (en) 2023-05-26

Similar Documents

Publication Publication Date Title
US11352369B2 (en) Pyridine and pyrimidine derivatives
US8796289B2 (en) Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases
TW202246255A (zh) Ｃｄｋ抑制劑及其使用方法
TW201938566A (zh) 囊性纖維化跨膜傳導調節因子之調節劑、醫藥組合物、治療方法及製造該調節劑之方法
EP3288931B2 (en) Certain protein kinase inhibitor
JP2016539990A (ja) ブロモドメイン阻害薬
EP3526210A1 (en) Bromodomain inhibitors
EP3609896A1 (en) Bromodomain inhibitors
HK40014442B (en) Polycyclic amide derivatives as cdk9 inhibitors
HK40014442A (en) Polycyclic amide derivatives as cdk9 inhibitors
HK1250985A1 (en) Polycyclic amide derivatives as cdk9 inhibitors
HK1250985B (en) Polycyclic amide derivatives as cdk9 inhibitors
BR112017027394B1 (pt) Composto, forma cristalina, composição farmacêutica e uso do mesmo
CA3020378C (en) Macrocyclic mcl1 inhibitors for treating cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180124

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210625

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230710

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240129

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240429

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240429

End annual number: 3

Start annual number: 1

PG1601 Publication of registration